Meeting
2023 ASCO Annual Meeting
AI-based HER2-low IHC scoring in breast cancer across multiple sites, clones, and scanners.
Authors
Patrick Frey
Mindpeak GmbH, Hamburg, Germany
Patrick Frey , Andreas Mamilos , Evgeny Minin , Ralf Banisch , Stefan Günther , Carolin Schmidt , Niklas Abele , Arndt Hartmann , Peter A. Fasching , Matthias Rübner , Hanna Huebner , Tobias Lang , Ramona Erber
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 516)
DOI
10.1200/JCO.2023.41.16_suppl.516
Abstract #
516
Poster Bd #
346
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Impact of HER2 assay sensitivity on the ability to detect tumors with low to ultra-low HER2 expression: A TMA study on more than 10,000 tumors from more than 100 tumor entities.
First Author: Maximilian Lennartz
Poster
2023 ASCO Annual Meeting
ERBB2 mRNA expression to distinguish HER2-low/neg breast cancer prognosis.
First Author: Yueping Liu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The HORIZON III retrospective exploratory analysis: HER2 expression amplification in colorectal cancer.
First Author: Fabiola Cecchi
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Computational pathology–based HER2 quantification to identify novel biomarkers in gastric cancer (GC).
First Author: Ansh Kapil